Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative performance increase of over 15% compared to the benchmark index within the next 6 to 12 months [9]. Core Views - The company achieved a revenue of 986 million yuan in the first three quarters of 2024, representing a year-on-year growth of 13.42%. The net profit attributable to shareholders was 18 million yuan, with a significant year-on-year increase of 123.77% [1]. - The company is experiencing robust growth in its life sciences and biopharmaceutical sectors, with a steady performance in its IVD (in vitro diagnostics) business. The introduction of high-performance products and breakthroughs in overseas markets are expected to drive rapid growth in related reagent products [1][2]. - The company has actively expanded its overseas business since 2022, leveraging differentiated solutions that combine reagents, consumables, and equipment. This strategy has led to significant breakthroughs in North America, Europe, and Southeast Asia, enhancing delivery efficiency and contributing to revenue growth [1][2]. Summary by Sections Financial Performance - For Q3 2024, the company reported a revenue of 337 million yuan, a year-on-year increase of 12.87%. The net profit attributable to shareholders was 2 million yuan, a decline of 57.55% year-on-year, while the non-recurring net profit was -15 million yuan, showing a year-on-year growth of 30.88% [1][3]. - The gross profit margin for the first three quarters of 2024 was 70.48%, a slight decrease of 0.45 percentage points year-on-year. The net profit margin improved by 10.67 percentage points year-on-year to 1.73% [1][2]. Cost Management - The sales expense ratio for the first three quarters of 2024 was 34.21%, down by 3.70 percentage points year-on-year. The management expense ratio was 16.47%, a decrease of 3.43 percentage points, and the R&D expense ratio was 21.76%, down by 6.85 percentage points [1][2]. Growth Forecast - The revenue forecast for 2024-2026 is adjusted to 1.416 billion yuan, 1.779 billion yuan, and 2.191 billion yuan, respectively, with year-on-year growth rates of 10%, 26%, and 23%. The net profit attributable to shareholders is projected to be 33 million yuan, 196 million yuan, and 314 million yuan for the same period, with year-on-year growth rates of 147%, 493%, and 60% [1][2].

表决结果：同意 3 票，反对 0 票，弃权 0 票。 监事会认为，公司 2024 年第三季度报告的编制和审议程序符合相关法律法 规及《公司章程》等内部规章制度的规定，内容与格式符合相关规定，真实、准 确、完整地反映了公司 2024 年第三季度的财务状况和经营成果等事项，不存在 任何虚假记载、误导性陈述或重大遗漏。在 2024 年第三季度报告编制过程中， 未发现公司参与报告编制和审议的人员有违反保密规定的行为。 证券代码：688105 证券简称：诺唯赞 公告编号：2024-057 报告具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn） 的《2024 年第三季度报告》。 南京诺唯赞生物科技股份有限公司 第二届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司(以下简称"公司")第二届监事会第十一 次会议（以下简称"会议"）于 2024 年 10 月 25 日以邮件方式向全体监事发出会 议通知，并于 2024 年 10 月 30 日以现场表决的方式 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2024-059 南京诺唯赞生物科技股份有限公司 关于拟对外投资设立控股公司暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 南京诺唯赞生物科技股份有限公司（以下简称"公司"）下属全资子公 司海南诺唯赞生物科技有限公司（以下简称"海南诺唯赞"）拟与海南嘉耀投资 合伙企业（有限合伙）（以下简称"海南嘉耀"）、海南晟健投资合伙企业（有 限合伙）（以下简称"海南晟健"）共同于英国投资设立控股公司 Logilet（UK） Limited（暂定名，以最终注册信息为准，以下简称"Logilet（UK）"或"新设 公司"），拟主要从事 Logicore 数字微流控系统在海外区域的市场准入、商业 推广和销售业务。新设公司注册资本为 1,000 万元人民币，约折合 137.93 万美 元，其中：海南诺唯赞拟直接投资，出资总额为 650 万元人民币，约折合 89.66 万美元，占比 65%；海南嘉耀拟通过全资子公司英属维尔京群岛公司 Newrgy Capita ...

本次股票上市流通总数为 232,148,088 股。 本次股票上市流通日期为 2024 年 11 月 15 日。 证券代码：688105 证券简称：诺唯赞 公告编号：2024-061 南京诺唯赞生物科技股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 232,148,088 股。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会《关于同意南京诺唯赞生物科技股份有限公司 首次公开发行股票注册的批复》（证监许可[2021]2367 号），公司首次公开发行人 民币普通股（A）股 40,010,000 股，并于 2021 年 11 月 15 日在上海证券交易所科 创板挂牌上市。首次公开发行股票完成后，公司总股本为 400，010，000 股，其中 有流通限制或限售安排的股票数量为 366,958,566 股，占公司发行后总股本的 91.7373%，无流通限制及限售安排的股票数量为 33,051,4 ...

Revenue and Profit - Revenue for the third quarter was RMB 336.64 million, a year-on-year increase of 12.87%[4] - Net profit attributable to shareholders of the listed company for the third quarter was RMB 1.997 million, a year-on-year decrease of 57.55%[4] - Total operating income for the first three quarters of 2024 was 985,911,100.96 yuan, an increase of 13.4% compared to 869,295,118.00 yuan in the same period of 2023[16] - Net profit for the first three quarters of 2024 was 17,011,556.32 yuan, a significant improvement from a net loss of 77,716,085.16 yuan in the same period of 2023[17] - Revenue for the first three quarters of 2024 reached 821.81 million yuan, a 15.2% increase compared to 713.40 million yuan in the same period of 2023[27] - Operating profit for the first three quarters of 2024 was 68.67 million yuan, a decrease of 18.2% from 83.95 million yuan in the same period of 2023[29] - Net profit for the first three quarters of 2024 was 74.18 million yuan, a 9.2% decrease compared to 81.69 million yuan in the same period of 2023[29] R&D and Expenses - R&D investment for the third quarter was RMB 72.02 million, a year-on-year decrease of 3.31%[4] - R&D expenses for the first three quarters of 2024 were 214,506,896.82 yuan, a 12.9% decrease from 246,376,539.96 yuan in the same period of 2023[16] - Total operating costs for the first three quarters of 2024 were 1,019,731,337.69 yuan, a 3.1% increase from 989,192,793.58 yuan in the same period of 2023[16] Assets and Liabilities - Total assets at the end of the reporting period were RMB 4.897 billion, a year-on-year decrease of 13.63%[4] - The company's monetary funds decreased significantly from 1,966,889,660.18 to 75,427,367.98[11] - Trading financial assets increased from 1,513,997,492.96 to 2,399,551,298.76[11] - Accounts receivable rose from 351,654,190.83 to 488,276,778.08[11] - Inventory increased from 346,248,153.48 to 375,570,547.45[11] - Total current assets decreased from 4,230,257,556.92 to 3,426,142,028.36[13] - Fixed assets decreased from 476,296,393.58 to 454,358,295.38[13] - Total non-current assets decreased from 1,515,914,981.54 to 1,471,335,988.35[13] - Short-term borrowings decreased from 1,133,961,526.05 to 456,776,139.73[13] - Accounts payable decreased from 146,816,201.02 to 83,306,770.71[13] - Total assets decreased from 5,746,172,538.46 to 4,897,478,016.71[13] - Total liabilities as of the end of the third quarter of 2024 were 959,428,364.16 yuan, a 44.1% decrease from 1,716,892,136.48 yuan at the end of the same period in 2023[15] - Total equity attributable to the parent company as of the end of the third quarter of 2024 was 3,939,299,368.85 yuan, a 2.2% decrease from 4,029,387,759.53 yuan at the end of the same period in 2023[15] - Total assets as of the end of the third quarter of 2024 were 4,897,478,016.71 yuan, a 14.8% decrease from 5,746,172,538.46 yuan at the end of the same period in 2023[15] - The company's monetary funds decreased to 42.70 million yuan from 1.83 billion yuan at the beginning of the period[23] - Accounts receivable increased to 553.41 million yuan from 410.52 million yuan at the beginning of the period[23] - Total assets decreased to 5.37 billion yuan from 5.72 billion yuan at the beginning of the period[25] - Short-term borrowings decreased to 456.78 million yuan from 876.79 million yuan at the beginning of the period[25] - Total liabilities decreased to 1.07 billion yuan from 1.38 billion yuan at the beginning of the period[26] - Shareholders' equity decreased to 4.30 billion yuan from 4.33 billion yuan at the beginning of the period[26] Cash Flow - The net cash flow from operating activities for the third quarter was negative RMB 25.74 million[4] - Cash received from sales of goods and services in the first three quarters of 2024 was 832,587,259.39 yuan, a 34.8% decrease from 1,277,346,901.36 yuan in the same period of 2023[19] - Cash flow from operating activities for the first three quarters of 2024 was 899,549,997.16 yuan, a 33.7% decrease from 1,356,086,403.17 yuan in the same period of 2023[19] - Net cash flow from operating activities was -99.99 million yuan, a decrease of 18.59 million yuan compared to the previous period[21] - Net cash flow from investing activities was 194.21 million yuan, compared to -909.43 million yuan in the previous period[21] - Net cash flow from financing activities was -867.58 million yuan, compared to 408.27 million yuan in the previous period[22] - Cash flow from operating activities for the first three quarters of 2024 was -294.83 million yuan, a significant decline from 262.48 million yuan in the same period of 2023[31] - Cash flow from investing activities for the first three quarters of 2024 was 222.95 million yuan, a notable improvement from -770.88 million yuan in the same period of 2023[31] - Cash flow from financing activities for the first three quarters of 2024 was -593.41 million yuan, compared to 163.99 million yuan in the same period of 2023[32] - The company's cash and cash equivalents at the end of the third quarter of 2024 were 42.69 million yuan, a sharp decrease from 762.60 million yuan at the end of the same period in 2023[32] Earnings Per Share and Shareholders - The company's basic earnings per share (EPS) for the third quarter was RMB 0.006, a year-on-year decrease of 42.41%[6] - The company's diluted earnings per share (EPS) for the third quarter was RMB 0.005, a year-on-year decrease of 46.10%[6] - The company's total number of ordinary shareholders at the end of the reporting period was 7,709[7] - Basic earnings per share for the first three quarters of 2024 were 0.05 yuan, compared to a loss per share of 0.19 yuan in the same period of 2023[18] - Basic earnings per share for the first three quarters of 2024 were 0.19 yuan, down from 0.20 yuan in the same period of 2023[30] Non-Recurring Items - The company's non-recurring gains and losses for the third quarter amounted to RMB 16.52 million[5] Return on Equity - The weighted average return on equity (ROE) for the third quarter was 0.05%, a decrease of 0.07 percentage points year-on-year[4]

华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作为 南京诺唯赞生物科技股份有限公司（以下简称"诺唯赞"或"公司"）首次公开发行 股票并在科创板上市持续督导阶段的保荐人，根据《证券发行上市保荐业务管理 办法》、《科创板上市公司持续监管办法（试行）》、《上海证券交易所科创板股票 上市规则》、《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运 作》等有关规定，对诺唯赞限售股份持有人持有的限售股份将上市流通情况进行 了认真、审慎的核查，并发表本核查意见，具体情况如下： 一、本次上市流通的限售股情况 根据中国证券监督管理委员会《关于同意南京诺唯赞生物科技股份有限公司 首次公开发行股票注册的批复》（证监许可[2021]2367 号），公司首次公开发行人 民币普通股（A）股 40,010,000 股，并于 2021 年 11 月 15 日在上海证券交易所 科创板挂牌上市。首次公开发行股票完成后，公司总股本为 400,010,000 股，其 中有流通限制或限售安排的股票数量为 366,958,566 股，占公司发行后总股本的 91.7373%，无流通限制及限售安排的股票数量为 33,051,4 ...

一、增加暂时闲置自有资金购买理财产品额度概况 （一）投资目的 证券代码：688105 证券简称：诺唯赞 公告编号：2024-058 南京诺唯赞生物科技股份有限公司 关于增加暂时闲置自有资金 购买理财产品额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司（以下简称"公司"或"诺唯赞"）于 2024 年 4 月 25 日召开了第二届董事会第九次会议、第二届监事会第七次会议， 审议通过了《关于使用暂时闲置自有资金购买理财产品的议案》，同意公司使用 额度不超过人民币 28 亿元（含本数）的暂时闲置自有资金购买安全性高、流动 性好、投资期限不超过 12 个月的低风险理财产品。具体内容详见公司于 2024 年 4 月 27 日披露于上海证券交易所网站（www.sse.com.cn）的《关于使用暂时 闲置自有资金购买理财产品的公告》（公告编号：2024-022）。 为了进一步提高公司自有资金的使用效率，增加公司现金资产收益，公司于 2024 年 10 月 30 日召开第二届董事会第十三次会议、第二 ...

第二届董事会独立董事专门会议第二次会议决议 南京诺唯赞生物科技股份有限公司(以下简称"公司")于 2024 年 10 月 23 日以邮件方式发出召开第二届董事会独立董事专门会议第二次会议的通知，并于 2024 年 10 月 25 日以通讯表决方式召开。本次会议应出席独立董事 3 名，实际 出席独立董事 3 名。本次会议的召集、召开程序符合《公司章程》《独立董事工 作制度》和有关法律法规的规定。经全体独立董事审议，会议形成决议如下： 审议通过《关于拟对外投资设立控股公司暨关联交易的议案》 南京诺唯赞生物科技股份有限公司 经审查，我们认为：公司本次对外投资设立控股公司暨关联交易事项符合《上 海证券交易所科创板股票上市规则》等法律法规、规范性文件及《公司章程》的 规定，符合公司战略发展规划与实际业务开展需要。公司及协议方均以货币出资， 同股同价，公平合理，不影响公司经营的独立性，不存在损害公司及股东特别是 中小股东利益的情形，一致同意公司本次对外投资暨关联交易事项，并同意提交 公司第二届董事会第十三次会议审议。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 夏宽云 蔡江南 董伟 （以下无正文） （此页无正文 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688105 证券简称：诺唯赞 公告编号：2024-060 南京诺唯赞生物科技股份有限公司 关于进行2024年度中期分红的公告 一、中期分红的前提条件及金额上限 根据公司 2023 年年度股东大会审议通过的《关于 2024 年中期分红方案的议 案》，公司可在当期盈利、累计未分配利润为正，现金流可以满足正常经营和持 续发展需求，且符合《公司章程》规定的其他利润分配条件的前提下，进行分红， 现金分红总额不超过相应期间归属于上市公司股东的净利润。 本次分红方案相关事宜，已经公司 2024 年 6 月 6 日召开的 2023 年年度股东 大会授权，由公司董事会制定具体方案并在规定期限内实施，具体详见公司分别 于 2024 年 5 月 7 日、6 月 7 日在上海证券交易所网站（www.sse.com.cn）披露 的《关于 2024 年中期分红方案的公告》《2023 年年度股东大会决议公告》（公 告编号：2024-031、038）。 1 分配比例：每10股派发 ...

核查意见 华泰联合证券有限责任公司 关于南京诺唯赞生物科技股份有限公司与关联方共同投资 设立控股子公司暨关联交易的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作为 南京诺唯赞生物科技股份有限公司（以下简称"诺唯赞"或"公司"）首次公开发行 股票并在科创板上市持续督导阶段的保荐人，根据《证券发行上市保荐业务管理 办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司 自律监管规则适用指引第 1 号—规范运作》《科创板上市公司持续监管办法（试 行）》等有关规定，对诺唯赞与关联方共同投资设立控股子公司暨关联交易进行 了认真、审慎的核查，并发表本核查意见，具体情况如下： 一、关联交易概述 基于公司国际业务战略布局，以及公司数字微流控业务海外商业化需要，公 司拟通过全资子公司海南诺唯赞生物科技有限公司（以下简称"海南诺唯赞"） 与海南嘉耀投资合伙企业（有限合伙）（以下简称"海南嘉耀"）、海南晟健投资 合伙企业（有限合伙）（以下简称"海南晟健"）共同于英国投资设立控股公司 Logilet（UK） Limited（暂定名，以最终注册信息为准，以下简称"Logilet （UK ...